Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

PAVmed Inc.

NASDAQ: PAVM · Industrial Applications and Services · 2 alerts · CIK 1624326

Share price
$1.75Close, Nov 16
Market cap
$14M
Shares outstanding
8MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PAVmed Inc. filings on SEC EDGAR ↗

8:05 AM ET 8-K
Financial Results

PAVmed Financial Results

PAVmed reported preliminary Q3 2026 financial results, highlighted by its subsidiary Lucid Diagnostics securing nationwide Medicare reimbursement for the EsoGuard test. The company reported $1.2 million in revenue for the quarter and noted that October saw record test volume of over 1,800 tests.

Term
Q3 2026

“We’re very encouraged by developments across the PAVmed portfolio. Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone. As Lucid’s largest common shareholder, PAVmed stands to benefit directly from Lucid’s substantial near-term revenue opportunity. Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are also now actively engaged with FDA on both PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value.”

Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.